Glycylpressin

Glycylpressin is a prescription injectable medication that contains the synthetic vasopressin analog terlipressin as its active ingredient; the specific strength is not disclosed, and it is supplied as an intravenous solution for use in the European Union. As a vasopressin V1‑receptor agonist, it produces vasoconstriction and raises systemic vascular resistance, which can be useful in managing certain acute bleeding and circulatory disorders in clinical practice.

Glycylpressin is indicated for several serious conditions where rapid reduction of portal pressure or systemic vasodilation is required, and it is administered under close medical supervision.

- Management of acute esophageal variceal bleeding. - Treatment of hepatorenal syndrome in patients with advanced liver disease. - Adjunctive therapy for septic shock refractory to standard vasopressors. - Control of severe hypotension associated with distributive shock when other agents are insufficient. - Support of hemodynamics in patients undergoing liver transplantation with portal hypertension.

The safety profile of Glycylpressin reflects its vasoconstrictive activity; side effects are reported across a range of frequencies.

Common: - Headache, usually mild and transient. - Nausea or vomiting, occurring shortly after infusion. - Transient elevation of systolic blood pressure. - Peripheral coldness or mild ischemia of extremities. - Flushing or erythema at the infusion site.

Serious: - Myocardial ischemia, presenting as chest pain or ECG changes. - Cardiac arrhythmias, including tachyarrhythmias or bradyarrhythmias. - Severe hypertension requiring pharmacologic intervention. - Ischemic limb events, such as pain, pallor, or loss of pulses. - Acute renal failure, manifested by rapid rise in serum creatinine.

When prescribing Glycylpressin, clinicians should consider several precautionary measures to minimize risk and ensure appropriate use.

- Assess cardiovascular status before initiation, especially a history of ischemic heart disease. - Monitor blood pressure and heart rate continuously during infusion. - Use caution in patients with renal impairment; adjust dosing as needed. - Avoid use in uncontrolled hypertension or severe peripheral vascular disease. - Evaluate for potential hypersensitivity to terlipressin or formulation components. - Consider pregnancy status; limited data are available, and use only if benefits outweigh risks.

Glycylpressin may interact with other agents that affect vascular tone or renal function; awareness of these interactions helps guide safe co‑administration.

Avoid: - Concomitant use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive hypertension risk. - Combination with vasodilators that may blunt therapeutic effect (e.g., nitroglycerin) unless closely monitored.

Use with caution: - Concurrent administration of nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) may increase risk of renal injury. - Beta‑blockers may mask tachycardia response; monitor heart rate. - Diuretics can exacerbate intravascular volume shifts; adjust fluid management accordingly.